Analysis of the miRNA–mRNA–lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data

Xiao, Bin; Zhang, Weiyun; Chen, Lidan; Hang, Jianfeng; Wang, Lizhi; Zhang, Rong; Liao, Yang; Chen, Jianyun; Ma, Qiang; Sun, Zhigang; Li, Linhai

doi:10.1016/j.gene.2018.03.011

Cited by 67 publications

(48 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interaction between lncRNA and miRNA constitutes an intricate molecular regulatory network, which has been certified to be connected to the development course of heterogeneous diseases. [ 29,30 ] One research represented that lncRNA MALAT1 knockdown could mollify LPS‐engendered AKI via the mediation of miR‐146a. [ 31 ] Other research showed that NEAT1 repression could allay sepsis‐evoked AKI via targeting miR‐204.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA HOXA‐AS2 mediates microRNA‐106b‐5p to repress sepsis‐engendered acute kidney injury

Wu¹,

Wang

2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

HOXA cluster antisense RNA 2 (HOXA‐AS2) is a long noncoding RNA associated with the development of numerous cancers. But, whether HOXA‐AS2 exhibits a certain function in sepsis‐engendered acute kidney injury (AKI) remains uninvestigated. We strived to unveil the role of HOXA‐AS2 in sepsis‐engendered AKI. The expression of HOXA‐AS2 in sepsis patients, animal models and lipopolysaccharide (LPS)‐impaired HK‐2 cells was primarily assessed via a real‐time quantitative polymerase chain reaction. The effects of HOXA‐AS2 on cell survival of HK‐2 cells under LPS irritation were evaluated after overexpression of HOXA‐AS2. The correlation between HOXA‐AS2 and microRNA (miR)‐106b‐5p was forecasted via bioinformatics software and verified by using a luciferase report system. Subsequently, the functions of miR‐106b‐5p in LPS‐damaged HK‐2 cells were reassessed. Western blot was used for the determination of Wnt/β‐catenin and nuclear factor‐κB (NF‐κB) pathways. HOXA‐AS2 expression was decreased in sepsis patients, animal operation group and LPS‐irritated HK‐2 cells. Overexpressed HOXA‐AS2 mollified LPS‐triggered impairment in HK‐2 cells. In addition, a negative mediatory relation between HOXA‐AS2 and miR‐106b‐5p was predicated. Synchronously, overexpressed miR‐106b‐5p counteracted the protection of HOXA‐AS2 in LPS‐damaged HK‐2 cells. Ultimately, Wnt/β‐catenin and NF‐κB pathways were hindered by HOXA‐AS2 via targeting miR‐106b‐5p. HOXA‐AS2 exhibited protection in sepsis‐engendered AKI via targeting miR‐106b‐5p and hindering the Wnt/β‐catenin and NF‐κB pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA HOXA‐AS2 mediates microRNA‐106b‐5p to repress sepsis‐engendered acute kidney injury

Wu¹,

Wang

2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…A similar study using TCGA data observed that the cross‐talk between miRNA, mRNA and lncRNAs may be an important feature in ER subtypes. Two lncRNAs network's nodes were highlighted as potential prognostic markers: LINC00092 and C2orf71 …”

Section: Lncrnas and Estrogen‐positive Subtypesmentioning

confidence: 99%

“…Two lncRNAs network's nodes were highlighted as potential prognostic markers: LINC00092 and C2orf71. 34 A signature with six lncRNAs was constructed to predict survival for patients with ER-positive status using TCGA data. 35 This signature comprises HAGLR, STK4-AS1, DLEU7-AS1, LINC00957, LINC01614…”

Section: Lncrnas and Estrogen-positive Subtypesmentioning

confidence: 99%

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

et al. 2019

View full text Add to dashboard Cite

Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non‐coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non‐coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.

show abstract

“…The prognostic value of LINC00511 in several cancers has been investigated in previous studies, which reveal that LINC00511 high expression is correlated with worse prognosis . For example, one previous study reveals that LINC00511 overexpression is correlated with worse OS and it is an independent prognosis factor for OS in patients with liver cancer .…”

Section: Discussionmentioning

confidence: 99%

Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo

Qiao

Qin

Liu³

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background:This study aimed to investigate the correlation of long intergenic noncoding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo. Methods:Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression-treated (OE-LINC00511) and nonsense overexpression-treated (OEcontrol) MG-63 and Saos-2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE-LINC00511 and OE-control xenografted mice.Results: LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P < .001), and its high expression correlated with increased tumor cell necrosis rate to neoadjuvant chemotherapy (P = .025) and prolonged OS (P = .010).In vitro, LINC00511 expression was decreased in osteosarcoma cell lines (including MG-63, U-2OS, Saos-2, and HOS) compared with osteoblast cell line (All P < .001).Cell proliferation was decreased at 48 hours (Both P < .01) and 72 hours (Both P < .001) (in MG-63 and Saos-2 cells); cell apoptosis was increased (P < .05) (in Saos-2 cells); cell migration and invasion were decreased (All P < .01) (in MG-63 cells and Saos-2 cells) in OE-LINC00511 compared with OE-control. In vivo, tumor volume was reduced at week 4 (P < .001), week 5 (P < .001), week 6 (P < .001) in OE-LINC00511 compared with OE-control. Tumor weight was declined in OE-LINC00511 than OEcontrol (P < .001). Conclusions: LINC00511 acts as a potential biomarker and therapeutic option for osteosarcoma.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.(HD-MTX) 10-12 g/m 2 intravenous drip within 5 hours, followed by intravenous injection of sodium folinate at 6 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 54 hours, 60 hours, 66 hours, and 72 hours (the complete of HD-MTX intravenous drip was defined as 0 hour), meanwhile, MTX concentration in plasma was monitored at 0 hour, 12 hours, 24 hours, 48 hours, and 72 hours; Day 8: adriamycin (ADM) 20 mg/m 2 /d × 3 days intravenous drip; Day 11: cisplatin (DDP) 120 mg/m 2 intravenous drip; Day 21: ifosfamide (IFO) 2 g/m 2 /d × 5 days intravenous drip, using Mesna to prevent hemorrhagic cystitis. Each cycle repeated every 3 weeks. A total of two cycles of IOR-OS/N-5 regimen were given to patients before surgery. When the neoadjuvant chemotherapy was completed, patients received amputation or limb-salvage surgery, which was decided with the consideration of patients' Ennecking stage, sensitivity to neoadjuvant chemotherapy, tu...

show abstract

Analysis of the miRNA–mRNA–lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data

Cited by 67 publications

References 46 publications

Long noncoding RNA HOXA‐AS2 mediates microRNA‐106b‐5p to repress sepsis‐engendered acute kidney injury

Long noncoding RNA HOXA‐AS2 mediates microRNA‐106b‐5p to repress sepsis‐engendered acute kidney injury

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo

Contact Info

Product

Resources

About